Beta-Hydroxyde Oily skin corrector
Oily skin and imperfections Oily skins express a lot of irregularities and discomforts. Shine, enlarged, dull complexion, microcysts, are all due to the sebum hyperproduction, together with a thickening of the horned layer. The directe regulation of sebum production is difficult to reach in cosmetics. Dead cells removal through exfoliation acts directly on some items such us dull complexion, pore size, prevention and correction of inflammatory lesions, and acts indirectly on the sebum production. For this, abrasion has become the main action in the oily skins segment.
Beta-Hydroxyde Molecular vectors Beta-Hydroxyde is a molecular association between salicylic and acacia polysaccharides. When associated to those polysaccharides, salicylic poorly penetrates and better targets the horned layer. The irritant potential is diminished as well. We have demonstrated that coupling potentialises the action of salicylic, as compared to free salicylic, on all the items of oily skins. Pore size, shine, black head, inflammatory lesions, while keeping an optimal comfort. Properties Keratolytic activity Origin Gum acacia extracted from Senegal acacia, (synthetic origin of petrochemical origin) Skincare Face anti-aging care, smoothing, radiance enhancer Face and hands anti-blemishes Oily skins anti-imperfection care
on on Exfoliating activity Comparison Beta-Hydroxyde salicylic / Free 14 Keratolytic activity 12 1 8 6 4 2 Free Libre salicylic BetaPROTACID Hydroxyde salicylic Evaluation of the discoloration speed of a pretreated zone with Dihydroxyacetone (DHA). Study carried out on the forearm of 15 volunteers, Application of a 2% Beta-Hydroxyde salicylic emulsion, versus free salicylic equivalent (1%) and, A 15-day treatment, Measurement of the discoloration with a chromameter. All the efficacy of salicylic. Targets the cutaneous surface Diffused quantity (µg/cm²) 12 12 1 1 8 8 6 6 4 4 2 2 2 4 Free salicylic 1 1 ß-hydroxyde ß-hydroxyde 8 8 ß-hydroxyde Beta-Hydroxyde 6 6 4 4 2 2 6 2 4 6 8 1 12 14 16 18 2 22 24 26 28 3 32 34 36 38 4 42 44 46 48 Time (hours) 8 1 12 14 16 18 2 22 24 26 28 3 32 34 36 38 4 42 44 46 48 Ex4 vivo cells 6 8study 1 12 on 14 Franz 16 18 2 22 24 26 28 3 32 34 36 38 4 42 44 46 48 Comparative transcutaneous penetration test of Beta-Hydroxyde versus free salicylic equivalent (1%) and, at ph 5, Measurement by spectrophotometry. 14, 14 Diffused quantity (µg/cm²) 2 12 12 12, 12 Free Acsalicylic Salycilique Ac Salycilique.4% 1, 1-29% 8 8, -42% 6 6, 4 4,.4% Beta-Hydroxyde.4% +3% 2 2,, Diffusion (after 48h) Diffusion Rediffusion Storage (after 72h) (in the biopsy) Released Storage Total Total Slows down the penetration speed : - 42%. Reduces cutaneous irritation. Released Released Storage Storage Total Total
Refines pore size Pore size reduction at D14 Beta Hydroxyde Ac Salycilique.4%,4% 3% 3% -7-7 -9-9 -11-11 -13-13 -15-15 -17-17 up to -1-1 -2-2 -2,5-2.5-3-3-3,5-3.5 Imprints visualization After a 28 day treatment with Beta-Hydroxyde 3% On 1 volunteers with oily skin and enlarged. 4 groups of 25 subjects using the product twice a day during 28 days: 1 formula, 1 formula contening.4% of Beta-Hydroxyde (.2% of salicylic ), 1 formula contening 3% of Beta-Hydroxyde ( of salicylic ), 1 formula contening of free salicylic (positive control). Evaluation are made at D, D14 et D28. Pore size is measured through imprints and laser video microscope analysis. Shine reduction Percentage of panelists who present a sebum diminishing at D14 Percentage of pore size diminishing versus D -5-5 Beta Hydroxyde Ac Salycilique.4%,4% 3% 3% -7-7 -9-9 -11-11 -13-13 -15-15 -17-17 up to -47.5% at D28 Sebum production diminishing at D14 on the whole panel.4%.4% 3% 3% -,5 -.5 % d'amélioration moyen vs T Percentage of porosity diminishing vs D -1-1 -1,5-1.5-2-2-2,5-2.5-3-3-3,5-3.5 : Statistically significant of D p<.5 Same as study refines pore size. Evaluation of sebum production by Sebutape patches. up to -13.5% at D28 3% 3% -1,5-1.5-47.5% at D28 Before treatment.4%.4% -,5 -.5 % d'amélioration moyen vs T -5-5 Percentage of porosity diminishing vs D Percentage of pore size diminishing versus D Reduction of number of at D14 up to -13.5% at D28
General improvement of oily skin Clinician evaluation after 14 days Beta-Hydroxyde.4% 1 1 Refined resserrés 4 3%2 % d'amélioration 15 15 255.4% { { 2 2 36 25 25 55 Perrcentage of improvement of the item 3 3 Beta-Hydroxyde 3% 153 12 51 uniformité du éclat du teint Blackheads comedons lésions Complexion Brightness Inflammateint inflammatoires eveness tory lesions { Perrcentage % d'amélioration of improvement of the item Clinician evaluation after 28 days Refined resserrés uniformité du éclat du teint comedons lésions Complexion Brightness Blackheads Inflammateint inflammatoires eveness tory lesions : Statistically different from T (p<.1) : Statistically different from T (p<.1) : Statistically different from T (p<.5) Same as study refines pore size. Evaluation of clinical aspect by a clinician, scorage according to an analogic scale. Auto-evaluation by panelists after 14 days Auto-evaluation by panelists after 28 days Beta-Hydroxyde.4% 9 Perrcentage of yes 1 1 9 Perrcentage of yes 1 1 8 8 8 8 7 Beta-Hydroxyde 3%.4% 3% 7 6 6 6 6 5 5 4 4 4 4 Less oily peau moins skin grasse Matified peauskin matifiée Less moins visible visibles Removed imperfections blemishes effacées Comfort confort Less oily Matified Less Removed Comfort You are peau moins peauskin matifiée moins blemishes imperfections confort vous êtes skin visible satisfied grasse visibles effacées satisfaites Same as study refines pore size. Auto-evaluation by panelists. Percentage of yes. Volunteer at D Volunteer at D28 after application of Beta-Hydroxyde 3%
Non cytotoxic Product presentation Summary file REF G11 DESCRIPTION Acacia polysaccharides and salicylic complex (powder in a 5/5 ratio) Regulatory data INCI, Acacia Senegal Gum. Japanese Cosmetic Denomination Sarichiru San (1274), Arabia Gomu (135). CAS# 69-72-7, 9-1-5. EINECS# 2-712-3, 232-519-5. FINAL SPECIFICATIONS Dry weight (15 hours, 15 C) 94.7 1.% Total Inorganic Matter Content (15 hours, 6 C) 17.2 22.6% Sugar Content (Anthrone) 15. 25.% content 44. 48.6% Appearance Powder Color Off white ph (3% water solution) 4.9 5.5 Aerobic Bacteria (3 C) <1/g Pathogens None Preservatives/Additives None Formulation Data Concentration of Use 1 to 5%. Incorporation method Add in the aqueous phase of the emulsion heated at 7 C 8 C and make the emulsion. Patent none
EUROPE BASF Beauty Creations 49, avenue Georges Pompidou 92593 Levallois-Perret Cedex France Tel: +33 () 1.49.64.53.97 Fax: +33 () 1.49.64.53.85 bcs-europe@basf.com AMERICAS Beauty Creations BASF Corporation 5 Health Sciences Drive Stony Brook, NY 1179 USA Tel: +1 (631) 38 23 Fax: +1 (631) 689 294 bcs-northamerica@basf.com JAPAN & ASIA-PACIFIC BASF Japan Ltd. 21F Roppongi Hills Mori Tower, 6-1-1 Roppongi, Minato-ku, Tokyo, 16-6121 JAPAN Tel: +81 () 3-3796-9214 Fax: +81 () 3-3796-9299 bcs-asia@basf.com Edition April 24, 212 Although all statements and information in this publication are believed to be accurate and reliable, they are presented gratis and for guidance only, and risks and liability for results obtained by use of the products or application of the suggestions described are assumed by the user. THERE ARE NO WARRANTIES OF ANY KIND. ALL EXPRESS AND IMPLIED WARRANTIES ARE DISCLAIMED. Statements or suggestions concerning possible use of the products are made without representation or warranty that any such use is free of patent infringement and are not recommendations to infringe any patent. The user should not assume that toxicity data and safety measures are indicated or that other measures may not be required. The claims and supporting data provided in this publication have not been evaluated for compliance with any jurisdiction s regulatory requirements and the results reported may not be generally true under other conditions or in other matrices. Users must evaluate what claims and information are appropriate and comply with a jurisdiction s regulatory requirements. Recipient of this publication agrees to (i) indemnify and hold harmless each entity of the BASF organization for any and all regulatory action arising from recipient s use of any claims or information in this publication, including, but not limited to, use in advertising and finished product label claims, and (ii) not present this publication as evidence of finished product claim substantiation to any regulatory authority.